Published in Ther Clin Risk Manag on January 14, 2015
Tapentadol in neuropathic pain cancer patients: a prospective open label study. Neurol Sci (2017) 0.75
Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain (2007) 6.98
Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain (2004) 5.51
Opioid complications and side effects. Pain Physician (2008) 4.24
Algorithm for neuropathic pain treatment: an evidence based proposal. Pain (2005) 3.92
Management of functional somatic syndromes. Lancet (2007) 2.90
EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol (2006) 2.86
Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg (2001) 2.63
Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology (2003) 2.62
Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med (2008) 2.44
Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology (1998) 2.30
The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med (2008) 2.26
Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology (1998) 2.17
Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin (2014) 2.15
Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract (2007) 2.02
Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes (2009) 1.99
Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage (2007) 1.91
Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain (2003) 1.85
The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain (2006) 1.82
Sensory afferent impulses originate from dorsal root ganglia as well as from the periphery in normal and nerve injured rats. Pain (1983) 1.72
(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther (2007) 1.72
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig (2010) 1.60
Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin (2013) 1.56
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther (2010) 1.50
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother (2010) 1.42
Neuronal and microglial mechanisms of neuropathic pain. Mol Brain (2011) 1.41
Influence of opiates on ion transport across rabbit ileal mucosa. Gastroenterology (1981) 1.39
Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther (1995) 1.38
Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain (2006) 1.36
Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract (2010) 1.35
Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett (2004) 1.30
Neuropathic pain: mechanisms and their clinical implications. BMJ (2014) 1.29
Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. Pain Pract (2006) 1.27
Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics (2009) 1.26
The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage (2010) 1.23
Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience (1997) 1.18
Responsible prescribing of opioids for the management of chronic pain. Drugs (2003) 1.17
Diabetic neuropathy. Postgrad Med J (2006) 1.16
The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain (2007) 1.16
Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann Neurol (1983) 1.14
Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain (2010) 1.13
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin (2011) 1.11
Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain Res Mol Brain Res (1997) 1.09
Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother (2012) 1.04
Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc (2006) 1.03
Peripheral neuropathy: differential diagnosis and management. Am Fam Physician (2010) 1.00
Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin (2009) 0.99
Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth (2014) 0.98
Chronic pain: a population-based study. Isr Med Assoc J (2008) 0.97
Management of opioid-induced constipation. Curr Pain Headache Rep (2001) 0.97
Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain (2010) 0.94
Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin (2012) 0.91
Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther (2009) 0.90
Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs (2011) 0.90
Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clin Drug Investig (2014) 0.89
Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician (2014) 0.89
Retrospective evaluation of medication appropriateness and clinical pharmacist drug therapy recommendations for home-based primary care veterans. Am J Geriatr Pharmacother (2007) 0.88
Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain (2013) 0.88
Enhancement of morphine analgesia by tricyclic antidepressants. Neuropharmacology (1979) 0.87
Tapentadol immediate release: a new treatment option for acute pain management. J Pain Res (2010) 0.87
Chronic low back pain analgesic studies--a methodological minefield. Pain (2010) 0.86
Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett (2008) 0.86
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin (2010) 0.85
Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs. Clin Ther (2012) 0.84
Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin Drug Investig (2013) 0.83
A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care (2014) 0.83
Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther (2009) 0.83
Pharmacologic management of diabetic peripheral neuropathic pain. Expert Opin Pharmacother (2013) 0.82
Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage (2006) 0.82
Medication pain management in the elderly: unique and underutilized analgesic treatment options. Clin Ther (2013) 0.80
Tapentadol in the management of chronic low back pain: a novel approach to a complex condition? J Pain Res (2011) 0.79
Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources. Clin J Pain (2012) 0.78
Tapentadol (nucynta) for treatment of pain. Am Fam Physician (2012) 0.77
Imputing at-work productivity loss using results of a randomized controlled trial comparing tapentadol extended release and oxycodone controlled release for osteoarthritis pain. J Occup Environ Med (2012) 0.77
Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. Adv Ther (2014) 0.77
Chronic pain in type 2 diabetic patients: a cross-sectional study in primary care setting. Eur J Gen Pract (2014) 0.77
Strong analgesics: working towards an optimal balance between efficacy and side effects. Eur J Pain (2010) 0.76
Peripheral neuropathy: evidence-based treatment of a complex disorder. Nurse Pract (2012) 0.76
Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther (2013) 0.76
Tramadol in pregnancy and lactation. Int J Obstet Anesth (2012) 0.76
Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. Clin Drug Investig (2014) 0.76
Acute pain in undergraduate medical education: an unfinished chapter! Pain Pract (2012) 1.66
Preventive analgesia for postoperative pain control: a broader concept. Local Reg Anesth (2014) 0.82
Effects of Anesthetic Management on Early Postoperative Recovery, Hemodynamics and Pain After Supratentorial Craniotomy. J Clin Med Res (2015) 0.76
Options for perioperative pain management in neurosurgery. J Pain Res (2016) 0.75
Challenges of pain control and the role of the ambulatory pain specialist in the outpatient surgery setting. J Pain Res (2016) 0.75